Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619856433
Authors: Ramacciotti E, Agati LB, Caffaro RA, Volpiani GG, Lopes RD, Comerota AJ, Fareed J
Direct oral anticoagulants (DOACs) are now widely used for the management of venous thromboembolism (VTE) that now includes cancer-associated thrombosis. This review summarizes recent data on VTE prophylaxis and treatment, new challenges, guidelines, and updates as well as the current place for DOACs on the emerging cancer-associated VTE management landscape.
PMID: 31234637 [PubMed - in process]